Article: TARGETED GENETICS ACQUIRING GENOVO, ALIGNING WITH BIOGEN.(Brief Article)

Gene therapy specialists Targeted Genetics Corp. and Genovo Inc. have decided to join forces and consolidate their technological expertise in a stock-swap acquisition valued at $67 million.

In addition to acquiring Genovo, Targeted Genetics announced a multi-product development and commercialization deal with Biogen Inc., a major shareholder of Genovo, worth up to $125 million.

Seattle-based Targeted Genetics will acquire privately held Genovo, of Sharon Hill, Pa., by issuing 6.63 million shares to Genovo's shareholders. The deal is valued at $67 million based on Targeted Genetics' closing stock price on Tuesday of $10.125 a share. Targeted Genetics' ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!